FairJourney Bio develops antibodies for pharmaceutical and biotechnology customers, including through Iontas in Cambridge. Partners Group has majority ownership alongside retained investors. [1][2][3][4]
01 / Behind the name
Who owns FairJourney Biologics?
Private · Majority stake held for clients; exact percentage not disclosed; Retained minority investment; exact current percentage not supplied [1][2][3][4]
01
Disclosed investment scope
FairJourney Biologics antibody research platform [1][2][3][4]
As reported · 10 Oct 2026
Partners Group's majority investment completed in 2024. GHO Capital reinvested a minority and founder António Parada retained a significant interest. The exact current split is not supplied. Iontas is the UK laboratory business; customer logos, including pharmaceutical groups, do not establish owned brands. [1][2][3][4]
Headquarters, incorporation and tax residence describe different things. A headquarters address does not tell you where all of a company’s tax is paid.
Follow the investment
Investors in FairJourney Biologics
Investor disclosures found
Selected investor disclosures have been found. Each names the held entity, basis and date; the complete investor register remains outside this review. A stake in a parent or operating company is shown against that entity. Dates refer to each disclosure and can differ from the profile review date. Evidence links are included with each record.
Held entity · FairJourney Biologics antibody research platform
Majority stake held for clients; exact percentage not disclosed
Ownership evidence checked ·
Partners Group's majority investment completed in 2024. GHO Capital reinvested a minority and founder António Parada retained a significant interest. The exact current split is not supplied. Iontas is the UK laboratory business; customer logos, including pharmaceutical groups, do not establish owned brands.
Held entity · FairJourney Biologics antibody research platform
Retained minority investment; exact current percentage not supplied
Ownership evidence checked ·
Partners Group's majority investment completed in 2024. GHO Capital reinvested a minority and founder António Parada retained a significant interest. The exact current split is not supplied. Iontas is the UK laboratory business; customer logos, including pharmaceutical groups, do not establish owned brands.
This ownership review has not established a dated UK cash corporation-tax payment for the relevant reporting entity.
United KingdomNot yet verified
UK corporation tax paid
Not yet verifiedCash payment
FairJourney Biologics · UK reporting scope not verified Annual reporting period not yet verified
The UK tax-paying entity, reporting period and cash corporation-tax payment have not been separately reconciled. Not verified does not mean no tax was paid. [1][2][3][4]
These figures have different scopes. They should not be added together or used as a like-for-like tax ranking.